Starsource Multitrade Limited , formerly known as Chemo Pharma Laboratories Limited, has officially confirmed to the Bombay Stock Exchange that it does not fall under the Large Corporate criteria as on March 31, 2026. This confirmation comes in compliance with specific SEBI operational circulars governing fund raising through debt securities by large entities.

Regulatory Compliance Framework

The company's disclosure was made pursuant to SEBI Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, updated as on April 13, 2022, and SEBI Circular SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023. These circulars specifically address Chapter XII regarding fund raising by issuance of debt securities by large corporates.

Company Disclosure Details

As part of the mandatory initial disclosure requirements, Starsource Multitrade Limited provided comprehensive information in the prescribed format:

Key Financial Position

The company reported nil outstanding borrowings as on March 31, 2026, as per the definition of borrowing specified in the aforementioned SEBI circulars. This zero borrowing position is a significant factor in the company's classification outside the Large Corporate framework.

Regulatory Implications

Under the SEBI framework, companies identified as Large Corporates are subject to specific mandatory borrowing requirements through debt securities. The circular stipulates that beginning from FY 2022, any shortfall in mandatory borrowing through debt securities would attract a fine of 0.20% of the shortfall, levied by Stock Exchanges at the end of the two-year block period.

Corporate Information

The confirmation was signed by Ruchit Mehta, Managing Director and Chief Executive Officer (DIN: 08810586), on behalf of the company. Starsource Multitrade Limited maintains its registered office in Kalyan, Maharashtra, and corporate headquarters in Ahmedabad, Gujarat, continuing its operations under the new corporate identity while maintaining compliance with all regulatory requirements.

Starsource Multitrade Limited has notified the Bombay Stock Exchange of its decision to claim exemption from the Annual Secretarial Compliance Report requirement for the financial year ending March 31, 2026. The company, formerly known as Chemo Pharma Laboratories Limited, is utilizing the exemption provision under Regulation 15(2) of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Regulatory Exemption Criteria

The company qualifies for the exemption based on specific financial thresholds established by SEBI regulations. Under Regulation 15(2), companies with paid-up equity share capital not exceeding ₹10 crore and net worth not exceeding ₹25 crore are exempt from certain compliance requirements.

Compliance Status and Future Commitments

Due to this exemption, Starsource Multitrade Limited is not required to submit the Corporate Governance Report for the year ended March 31, 2026, under Regulation 24A of SEBI Listing Regulations. The company has noted that audited figures for the year ended March 31, 2026, are still awaited, preventing the exact determination of the current net worth.

The company has provided assurance regarding future compliance obligations. Management has undertaken that if and when these regulations become applicable to the company, it will comply with all requirements within six months from the date the provisions become applicable.

Company Background

Starsource Multitrade Limited, with CIN L46900MH1942PLC003556, operates from its registered office at 5 - Kumud Apartment CHS Ltd, Karnik Road, Chikan Ghar, Kalyan - 421301, India. The company maintains its corporate headquarters at 1016, North Plaza, Near D Mart, Motera, Ahmedabad - 380005, India. The communication to BSE was signed by Ruchit Mehta, Managing Director & Chief Executive Officer, bearing DIN 08810586.